Q3 Earnings Estimate for CNTB Issued By Leerink Partnrs

Key Points

• Leerink Partners estimates Connect Biopharma's Q3 2025 earnings per share at ($0.25), compared to the consensus estimate of ($0.22) for the full year.
• Connect Biopharma recently reported ($0.19) EPS for a previous quarter, exceeding expectations by $0.07.
• Institutional investors own 58.72% of Connect Biopharma's stock, with new stakes added by firms such as XTX Topco Ltd and AlphaCore Capital LLC in Q2.

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Free Report) - Analysts at Leerink Partnrs issued their Q3 2025 earnings per share estimates for shares of Connect Biopharma in a research report issued on Wednesday, August 13th. Leerink Partnrs analyst T. Smith forecasts that the company will earn ($0.25) per share for the quarter. The consensus estimate for Connect Biopharma's current full-year earnings is ($0.22) per share. Leerink Partnrs also issued estimates for Connect Biopharma's Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($0.94) EPS, FY2026 earnings at ($0.55) EPS, FY2027 earnings at ($0.29) EPS, FY2028 earnings at ($0.64) EPS and FY2029 earnings at ($0.37) EPS.

A number of other research firms have also commented on CNTB. Northland Capmk upgraded Connect Biopharma to a "strong-buy" rating in a research report on Tuesday, July 22nd. HC Wainwright restated a "buy" rating and set a $7.00 price target on shares of Connect Biopharma in a research report on Wednesday, August 13th. Finally, Wall Street Zen upgraded Connect Biopharma to a "hold" rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Strong Buy" and a consensus price target of $7.00.

Connect Biopharma Price Performance

NASDAQ CNTB traded up $0.10 during trading hours on Monday, reaching $1.83. 121,848 shares of the company's stock were exchanged, compared to its average volume of 159,527. Connect Biopharma has a one year low of $0.51 and a one year high of $2.86. The firm has a fifty day moving average of $1.62 and a 200-day moving average of $1.08. The company has a quick ratio of 7.24, a current ratio of 7.24 and a debt-to-equity ratio of 0.01.

Hedge Funds Weigh In On Connect Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of CNTB. AlphaCore Capital LLC bought a new position in Connect Biopharma in the second quarter valued at approximately $78,000. Koa Wealth Management LLC bought a new position in Connect Biopharma in the second quarter valued at approximately $49,000. Finally, XTX Topco Ltd bought a new position in Connect Biopharma in the second quarter valued at approximately $29,000. 58.72% of the stock is owned by institutional investors.

Connect Biopharma Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.